Psychedelic News2023-08-08T14:20:44+02:00

News and Press Releases

  • Newcourt to Acquire Psyence’s Clinical Trials Division

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

January 10, 2023|

Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.

Psyence Signs Letter of Intent with Australian CRO iNGENū

January 9, 2023|

Psyence announce it has signed a Letter of Intent (LOI) with Contract Research Organisation (CRO) iNGENū to execute Psyence’s strategy of clinical development in palliative care. iNGENū is an Australian full-service CRO specialising in clinical trials for psychoactive pharmaceuticals.

News and Press Releases

Psyence In The News

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility
Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain
Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand
Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa
In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.
Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities
Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller
Go to Top